Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or Iraq, with or without Reported Burn Pit and Toxic Smoke Exposure

Dickran Kazandjian, Christin DeStefano, Alexander Dew, Elizabeth Hill, Katie Thoren, Ola Landgren

Blood (2023) 142 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2023-182169

Published: 2023

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

Epidemiological Profile of Polycythemia Vera Patients Diagnosed during 2016-2020: An Ethnic Variation in Armenia

Maria Badikyan, Nare Martirosyan, Liana Hambardzumyan, Alisa Movsisyan, Arusyak Ivanyan, Nata Melkikyan, Gevorg Tamamyan, Dickran Kazandjian, Astghik Voskanyan

Blood (2023) 142 (Supplement 1): 6410.

https://doi.org/10.1182/blood-2023-190299

Published: 2023

Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal

Blood (2023) 142 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2023-178735

Published: 2023

Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2023-186241

Published: 2023

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN):Multi-Center Collaboration and Global Registry Program

Blood (2023) 142 (Supplement 1): 1543.

https://doi.org/10.1182/blood-2023-188546

Published: 2023

Journal Articles

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Andrew Kowalski, Jillian Lorayne Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James E. Hoffman, Dickran Kazandjian, Ola Landgren

Blood (2023) 142 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2023-187086

Published: 2023

Journal Articles

Long Term Cancer Risk of U.S. Service Members Exposed to Burn Pits during Military Deployment to Iraq from 2006-2008: A Retrospective Cohort Study

Robert Sgrignoli, Matthew Joseph Rendo, Alexander Dew, Ian Robertson, Sarah Darmon, Ola Landgren, Dickran Kazandjian, Christin DeStefano

Blood (2023) 142 (Supplement 1): 6621.

https://doi.org/10.1182/blood-2023-173557

Published: 2023

Journal Articles

CYT-338 NK Cell Engager Mutispecific Antibody Engagement of NKp46 Activation Receptor Overcomes Anti-CD38 Mab Mediated Fratricide of NK Cells and Accords Enhanced Cancer Immunotherapy

Vishal Khairnar, Liang Lin, Hao-Ming Chang, Sourindra Maiti, Solgalim Diaz, Ofer Mandelboim, Tariq Mughal, Dan Chiche, Elisabetta Burchi, Armand Bensussan, Jean Kadouche, Ola Landgren, Dickran Kazandjian, Armin Rath, Daniel Teper, Wei Li, Antonio Arulanandam

Blood (2023) 142 (Supplement 1): 6725.

https://doi.org/10.1182/blood-2023-190613

Published: 2023

Journal Articles

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Ola Landgren, Francesco Maura, Dickran Kazandjian

Blood (2023) 142 (Supplement 1): 3392.

https://doi.org/10.1182/blood-2023-186834

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Co-Occurrence of Familial Mediterranean Fever and Hematologic Malignancies: Case Report Series

Blood (2023) 142 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2023-188724

Published: 2023

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2023) 142 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2023-180939

Published: 2023

Journal Articles

Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

Blood (2022) 140 (Supplement 1): 249–251.

https://doi.org/10.1182/blood-2022-165500

Published: 2022

Journal Articles

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Ola Landgren, Dickran Kazandjian, Ashleigh O'Connell, Gregory Finn, Noopur Raje

Blood (2022) 140 (Supplement 1): 10172–10173.

https://doi.org/10.1182/blood-2022-166854

Published: 2022

Journal Articles

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

Blood (2022) 140 (Supplement 1): 430–432.

https://doi.org/10.1182/blood-2022-167390

Published: 2022

Journal Articles

A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Bhagirathbhai Dholaria, Admasu Mamuye, Diana Yurewicz, Kristina Dabovic, Amy Yuet, Rafat Abonour, Kevin R. Kelly, Timothy J. Voorhees, Dickran Kazandjian

Blood (2022) 140 (Supplement 1): 12621–12622.

https://doi.org/10.1182/blood-2022-168960

Published: 2022

Journal Articles

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Blood (2022) 140 (Supplement 1): 1137–1139.

https://doi.org/10.1182/blood-2022-160308

Published: 2022

Journal Articles

Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study

Hang Quach, Rajeev Rajagopal, Andrew Spencer, Michael Low, Dickran Kazandjian, Rocco Crescenzo, Chenmu Du, Sheel Patel, Vaibhav Mundra, Huan Cheng, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7269–7271.

https://doi.org/10.1182/blood-2022-169666

Published: 2022

NARROW

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or Iraq, with or without Reported Burn Pit and Toxic Smoke Exposure

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Epidemiological Profile of Polycythemia Vera Patients Diagnosed during 2016-2020: An Ethnic Variation in Armenia

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN):Multi-Center Collaboration and Global Registry Program

Tocilizumab Prophylaxis for Patients Treated with Teclistamab: A Single-Center Experience

Long Term Cancer Risk of U.S. Service Members Exposed to Burn Pits during Military Deployment to Iraq from 2006-2008: A Retrospective Cohort Study

CYT-338 NK Cell Engager Mutispecific Antibody Engagement of NKp46 Activation Receptor Overcomes Anti-CD38 Mab Mediated Fratricide of NK Cells and Accords Enhanced Cancer Immunotherapy

Advance Multicenter Clinical Trial: MRD-Driven Therapy in Newly Diagnosed Multiple Myeloma Patients

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Co-Occurrence of Familial Mediterranean Fever and Hematologic Malignancies: Case Report Series

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin

A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only